Quick Answer
Mct Oil Cognition Randomized Trial has evidence relevant to safety, limits, and clinician-discussion contexts, but conclusions should stay close to the cited sources. One representative finding is: EK supplementation was associated with a statistically significant improvement in cognitive performance compared with placebo (SMD = 0.29, 95% CI 0.16-0.41; p p = 0.083), study duration (acute vs.
Key Takeaways
- 01EK supplementation was associated with a statistically significant improvement in cognitive performance compared with placebo (SMD = 0.29, 95% CI 0.16-0.41; p p = 0.083), study duration (acute vs. [Bonnechère B (2026)]
- 02Discussion EK supplementation is associated with modest improvements in cognitive performance across diverse populations and study designs. [Bonnechère B (2026)]
- 03Introduction Cognitive function is closely linked to brain energy metabolism and may be compromised by aging, metabolic stress, and neuropsychiatric disease. [Bonnechère B (2026)]
- 04Ketone bodies can serve as an alternative cerebral fuel and may also exert signaling effects relevant to cognition. [Bonnechère B (2026)]
The current Migaku evidence database contains 2 reusable source documents for Mct Oil Cognition Randomized Trial. This answer focuses on safety, limits, and clinician-discussion contexts.
- EK supplementation was associated with a statistically significant improvement in cognitive performance compared with placebo (SMD = 0.29, 95% CI 0.16-0.41; p p = 0.083), study duration (acute vs. [Bonnechère B (2026); evidence level 1]
- Discussion EK supplementation is associated with modest improvements in cognitive performance across diverse populations and study designs. [Bonnechère B (2026); evidence level 1]
- Introduction Cognitive function is closely linked to brain energy metabolism and may be compromised by aging, metabolic stress, and neuropsychiatric disease. [Bonnechère B (2026); evidence level 1]
- Ketone bodies can serve as an alternative cerebral fuel and may also exert signaling effects relevant to cognition. [Bonnechère B (2026); evidence level 1]
- Background and objectives Postprandial hyperglycemia is a modifiable determinant of type 2 diabetes risk and vascular complications. [Kodama K (2026); evidence level 4]
Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording.
This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.
Sources